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OBJECTIVES This study sought to determine the short- and long-term outcome of primary coronary
angioplasty and thrombolytic therapy for acute myocardial infarction (AMI) in patients older
than 75 years of age.
BACKGROUND The benefit of reperfusion therapy in elderly patients with AMI is uncertain, although elderly
people account for a large proportion of deaths.
METHODS We randomly assigned a total of 87 patients with an AMI who were older than 75 years to
treatment with angioplasty or intravenous (IV) streptokinase. Clinical outcome was measured
by taking the end points of death and the combination of death, reinfarction or stroke during
follow-up.
RESULTS The primary end point, a composite of death, reinfarction or stroke, at 30 days had occurred
in 4 (9%) patients in the angioplasty group as compared with 12 (29%) in the thrombolysis
group (p  0.01, relative risk [RR]: 4.3, 95% confidence interval [CI]: 1.2 to 20.0). At one
year the corresponding figures were 6 (13%) and 18 (44%), respectively (p  0.001, RR: 5.2,
95% CI: 1.7 to 18.1).
CONCLUSIONS In this series of patients with AMI who were older than 75 years, primary coronary
angioplasty had a significant clinical benefit when compared with IV streptokinase
therapy. (J Am Coll Cardiol 2002;39:1723–8) © 2002 by the American College of
Cardiology Foundation
Mortality among older patients with acute myocardial
infarction (AMI) is higher than for patients of younger age
(1–5). Reperfusion therapy may improve survival, but the
effectiveness of thrombolytic therapy in elderly patients has
recently been questioned (6–8). Primary coronary angio-
plasty is an alternative tool to accomplish reperfusion of the
infarct-related vessel (IRV) with at least equal or greater
clinical benefit, and with a lower risk of intracerebral
hemorrhage, when compared with thrombolytic therapy
(9–12). On the other hand, percutaneous coronary inter-
ventions carry an increased procedural risk in older patients
when compared with those of younger age (13). An analysis
See page 1729
of data from the Primary Angioplasty for Myocardial
Infarction (PAMI), the Zwolle and the Mayo Clinic studies
suggests a stronger benefit of primary angioplasty over
thrombolytic therapy with increasing age (14). However,
the place of primary coronary angioplasty in elderly patients
with AMI has not yet been determined in a randomized
comparison, as most studies recruited only few elderly
patients. We performed a prospective randomized trial
comparing primary coronary angioplasty with intravenous
(IV) streptokinase therapy in patients with AMI and 76
years or older and no contraindications for thrombolytic
therapy. We chose streptokinase as the thrombolytic drug in
our study because the risk of stroke is lower with this agent,
and it is still the most widely used pharmacologic reperfu-
sion therapy in the Netherlands (15).
METHODS
From March 1996 until April 1999, 87 patients of 76 years
or older referred to our hospital directly with AMI and
without contraindications for thrombolytic therapy were
randomly assigned to treatment with IV streptokinase or
immediate angiography and, if possible, subsequent angio-
plasty. All patients admitted to our coronary care unit with
the diagnosis of AMI who were 76 years or older, but not
fulfilling the study inclusion criteria, were registered in a
separate database.
Inclusion criteria were as follows: symptoms of AMI that
persisted for more than 30 min accompanied by an elevation
of more than 1 mm (0.1 mV) in the ST segment in two or
more contiguous electrocardiographic leads; and presen-
tation within 6 h after the onset of symptoms (or between
6 h and 24 h, if there was evidence of continuing ischemia).
Contraindication to thrombolytic therapy was defined as
previous stroke or other known intracranial disease,
recent trauma or surgery, refractory hypertension (systolic
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 180 mm Hg, diastolic 110 mm Hg), active bleeding or
prolonged cardiopulmonary resuscitation. Before random-
ization we recorded each patient’s age, gender, Killip class
on admission (16), electrocardiographic site of infarction,
history of previous infarction, heart rate, time of onset of
symptoms and time of hospital admission. The catheteriza-
tion laboratory and the dedicated house staff were available
24 h, 7 days a week.
All patients received 450 mg of aspirin intravenously,
followed by 80 mg of aspirin per day orally and IV
nitroglycerin in a dose designed to maintain a systolic blood
pressure of 110 mm Hg. Intravenous heparin was given in a
dose designed to maintain the activated partial thrombo-
plastin time between two and three times the normal value
for at least two days. This partial thromboplastin time was
measured twice a day. Patients assigned to streptokinase
received 1.5 million U intravenously over a period of 1 h. In
patients assigned to angioplasty treatment, coronary angiog-
raphy was performed as soon as possible. Both coronary
arteries were visualized; left ventriculography was not per-
formed routinely. Coronary angioplasty was performed at
the investigator’s discretion using any approved techniques
and devices. Patients who received a stent were treated with
ticlopidine, 250 mg, twice a day for two weeks. All cinean-
giograms were reviewed by two experienced investigators
not involved in other parts of the study. Flow through the
IRV was scored according to the Thrombolysis In Myocar-
dial Infarction (TIMI) flow grading, before and after the
angioplasty procedure (17). Agreement on flow and extent
of coronary artery disease was reached in all cases. The time
from admission to the initiation of therapy was calculated as
the time to the start of the streptokinase infusion or the first
balloon inflation.
Recurrent AMI was defined as chest pain, changes in the
ST-T segment and a second increase in the creatine kinase
level to more than two times the upper limit of normal or an
increase of 200 U/l over the previous value if the level had
not dropped below the upper limit of normal.
The primary end point was the composite of death,
reinfarction or stroke at 30 days after randomization. The
secondary end points were:
1. The composite of death, reinfarction and stroke at one
year.
2. Enzymatic infarct size as was calculated from lactate
dehydrogenase (LDH) release in the plasma during the
first 72 h after symptom onset. This method is equal to
estimation of infarct size from a-hydroxybutyrate dehy-
drogenase and has previously been described in detail
(18). Cumulative enzyme release from five to seven serial
measurements up to 72 h after symptom onset was
calculated with blinding to all data other than hospital
registration number and date of birth.
3. Left ventricular ejection fraction, as was measured before
discharge by radionuclide ventriculography using the
multiple gated equilibrium method following the label-
ling of red blood cells of the patient with 99mTc-
pertechnetate. A General Electric 300 gamma camera
with a low-energy all-purpose parallel-hole collimator
was used. Global ejection fraction was calculated by a
General Electric Star View (Milwaukee, Wisconsin)
computer using the fully automatic PAGE program. The
use of this software program protects against operator
bias. This technique has been validated by us before (18).
The study protocol was approved by the institutional
ethics committee, and all patients gave oral informed
consent. Before randomization it was ascertained that a
catheterization laboratory was immediately available for
coronary intervention. Randomization was performed using
a telephone randomization service and was stopped early
(April 1999) because a significant difference in the primary
end point was found. Follow-up data were collected in
March 2000. All clinical and outpatient records were
reviewed, and general practitioners were contacted by tele-
phone.
Statistical analysis. All end points were analyzed accord-
ing to the principle of intention-to-treat. A chi-square
statistic was calculated to test differences between propor-
tions with calculations of relative risks (RR) and exact 95%
confidence intervals (CIs). Fisher exact test was used if there
was an expected cell value of 5. The Student t test or the
Mann-Whitney U test was used to compare continuous
values. Survival and survival without recurrent infarction or
stroke were calculated by the Kaplan-Meier product-limit
method (19). Survival analysis over the total follow-up
period was also performed by fitting Cox proportional
hazards model (20). Because of the small sample size, this
was not used as a multivariate model but enabled us to
calculate hazard ratios, which may be interpreted as RRs,
with 95% CIs. Continuous variables are summarized by
using medians (with 25th, 75th percentiles) unless other-
wise indicated; discrete variables are represented as frequen-
cies and percentages. A p value of 0.05 was considered to
indicate statistical significance.
The sample size was estimated on the basis of the
following assumption: the 30-day incidence of death, rein-
farction or stroke in the thrombolysis group would be 30%,
whereas this incidence in the angioplasty group would be
15% (14,21). At alpha-level 5% and beta-level 20%, the
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number of patients required was 266, with 133 patients in
each group.
RESULTS
During the study period, a total number of 164 patients
older than 75 years and with the diagnosis of AMI were
admitted to our hospital. Of these patients, 87 fulfilled the
criteria for inclusion in our study. Of the patients random-
ized, 46 were assigned to primary angioplasty treatment and
41 patients were assigned to treatment with streptokinase.
The baseline characteristics are summarized in Table 1, and
the two patient groups were well balanced with regard to the
most important determinants of mortality and morbidity.
Six patients in the group assigned to angioplasty and four in
the streptokinase group were randomized more than 6 h
after symptom onset (p  0.7). Patients were followed for a
mean of 20  6 months, and no patient was lost to
follow-up. The clinical results are given in Table 2. The
mean time from hospital admission to start of streptokinase
infusion was 31  15 min. Of the patients randomized to
invasive treatment, 45 underwent coronary angiography,
and 41 actually underwent angioplasty with a procedural
success rate of 90% (37 of 41), defined as a residual stenosis
of the culprit lesion of 50% and TIMI 3 flow through the
IRV. One patient died before angiography could be per-
formed. Two patients were referred for bypass surgery, and
in two patients a conservative treatment was chosen. Four
strokes occurred, one in the angioplasty group (one week
after treatment with an intra-aortic balloon pump) and three
in the streptokinase group (all on the day of treatment), of
whom one died. Of the patients treated with angioplasty,
51% (21 of 41) did receive a stent, whereas the remaining
patients underwent balloon angioplasty only. None of the
study patients received glycoprotein IIb/IIIa inhibitors dur-
ing the study period. The mean time from hospital admis-
sion to first balloon inflation was 59  19 min (range: 33 to
120 min). One patient in each group was treated with an
intra-aortic balloon counterpulsation device in the immedi-
ate postinfarction period. After 30 days, three patients (7%)
in the angioplasty group died, compared with nine patients
(22%) in the thrombolysis group (p  0.04), resulting in an
RR for patients treated with thrombolysis of 4.0 (95% CI:
0.9 to 24.6) compared with patients treated with primary
angioplasty. The composite predefined end point of death,
recurrent infarction and stroke at 30 days occurred in 4 (9%)
Table 1. Baseline and Clinical Characteristics of the Two Patient Groups
Angioplasty
(n  46) p Value
Streptokinase
(n  41)
Age, yrs 80 (77–84) 0.17 81 (78–84)
Male gender, n (%) 22 (48) 0.31 25 (61)
Systemic hypertension, n (%) 12 (27) 0.86 10 (24)
Diabetes mellitus, n (%) 11 (24) 0.60 7 (17)
Previous AMI, n (%) 6 (13) 0.82 7 (17)
Anterior AMI, n (%) 23 (50) 0.89 19 (46)
Previous CABG, n (%) 3 (7) 0.47 4 (10)
Killip class III or IV, n (%) 6 (13) 0.74 4 (10)
Heart rate on admission, beats/min 69 (55–78) 0.74 65 (50–80)
Systolic blood pressure, mm Hg 120 (100–145) 0.34 120 (100–140)
Time onset–admission, min (range) 207 (60–1,020) 0.62 212 (25–700)
Multivessel disease, n (%) 39 (87) — —
Initial TIMI flow grade IRV, n (%)
0 30 (67)
1 4 (9)
2 6 (13)
3 5 (11)
Values presented are as median and 25th and 75th percentiles or number (%), unless stated otherwise.
AMI  acute myocardial infarction; CABG  coronary artery bypass grafting; IRV  infarct-related vessel; TIMI 
Thrombolysis In Myocardial Infarction.
Table 2. Clinical Course of the Two Patient Groups
Angioplasty
(n  46) p Value
Streptokinase
(n  41)
Mortality in-hospital,
n (%)
3 (7) 0.07 8 (20)
Stroke, n (%) 1 (2) 0.34 3 (7)
Recurrent AMI, n (%) 1 (2) 0.01 6 (15)
Bleeding (noncerebral) 5 (11) 0.72 3 (7)
Maximum CK 829 (422–1,425) 0.71 997 (448–1,568)
LDH Q72 1,442 (781–2,022) 0.10 1,772 (996–2,672)
Days on CCU 2 (1–3) 0.003 2 (2–3)
Total days in hospital 5 (3–10) 0.95 5 (3–10)
Number of readmissions 13 0.29 9
Ejection fraction %,
mean  SD
43  10 0.34 44  11
Additional CABG/PTCA,
n (%)
2 (4) 0.41 4 (10)
Death during follow-up,
n (%)
7 (15) 0.04 13 (32)
Combined clinical end
point during follow-up,
(death, stroke
or reinfarction), n (%)
9 (20) 0.01 18 (44)
Values presented are as median and 25th and 75th percentiles or number (%), unless
stated otherwise.
AMI  acute myocardial infarction; CABG  coronary artery bypass grafting
surgery; CCU  Coronary Care Unit; CK  creatine kinase; LDH Q72  lactate
dehydrogenase release in the plasma during the first 72 h after symptom onset;
PTCA  percutaneous transluminal coronary angioplasty.
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patients in the angioplasty treated patients versus 12 (29%)
in the thrombolysis group (p  0.01, RR: 4.3, 95% CI: 1.2
to 20.0).
Survival and survival without the combined clinical end
point curves are depicted in Figures 1 and 2. Follow-up was
complete in all patients. After one year, 5 patients (11%) in
the angioplasty group and 12 patients (29%) in the throm-
bolysis group had died (p  0.03), resulting in an RR for
patients treated with thrombolysis of 3.4 (95% CI: 1.0 to
13.5) compared with patients treated with primary angio-
plasty. The corresponding figures for the composite end
point after one year were 6 (13%) and 18 (44%), respectively
(p  0.001, RR: 5.2, 95% CI: 1.7 to 18.1). The significant
difference in reaching the primary end point between the
two groups was the reason to end the study before the
anticipated number of patients was included.
During the total follow-up period (mean: 24 months),
there were 20 deaths: 7 (15%) in the angioplasty group and
13 (32%) in the streptokinase group (p  0.04, RR: 2.5,
95% CI: 1.0 to 6.2). The corresponding figures for the
composite end point were 9 (20%) and 18 (44%), respec-
tively (p  0.003, RR: 3.1, 95% CI: 1.4 to 7.0). The
Kaplan-Meier curves are depicted in Figures 1 and 2.
The in-hospital mortality of the 77 patients not included
in our study was 21%, and their baseline characteristics are
given in Table 3. They were compared with baseline
characteristics and in-hospital outcome of the study pa-
tients.
Six patients retrospectively fulfilled the criteria for study
entry but were not randomized. The reasons for not
including patients in the study were: not fulfilling the
electrocardiogram (ECG) criteria, 27 patients; contraindi-
cations for thrombolysis, 23 patients; beyond the study time
window, 11 patients; referral from other hospitals for rescue
angioplasty, 5 patients; already participating in other study,
3 patients; and subacute stent thrombosis, 2 patients.
DISCUSSION
We conducted a randomized trial in elderly patients, com-
paring thrombolytic therapy and primary coronary angio-
plasty for the treatment of AMI. The benefit with regard to
30-day survival did reach statistical significance (p  0.04,
RR: 4.0, 95% CI: 0.9 to 24.6), and the incidence of the
predefined composite end point of death, recurrent infarc-
tion and stroke after 30 days was significantly lower in the
angioplasty treated patient group (p  0.01, RR: 4.3, 95%
CI: 1.2 to 20.0). This was the reason why the study was
halted prematurely. The long-term follow-up data showed a
statistically significant benefit with regard to survival after
one year (p  0.03, RR: 3.4, 95% CI: 1.0 to 13.5) and the
combined clinical end point of death, recurrent AMI or
stroke (p  0.001, RR: 5.2, 95% CI: 1.7 to 18.1) of
angioplasty treatment over thrombolytic therapy.
In the initial phase after the index infarction, infarct size,
as was estimated from cumulative LDH release in the
Figure 1. The Kaplan-Meier curve compares the overall survival for
patients randomized for angioplasty treatment (solid line) and thrombol-
ysis treatment (dashed line) during 24 6 months of follow-up (p 0.04,
relative risk: 2.5, 95% confidence interval: 1.0 to 6.2).
Figure 2. The Kaplan-Meier curve compares the overall survival free of
recurrent infarction or stroke for patients randomized for angioplasty
treatment (solid line) and thrombolysis treatment (dashed line) during
24  6 months of follow-up (p  0.003, relative risk: 3.1, 95% confidence
interval: 1.4 to 7.0).
Table 3. Characteristics and In-Hospital Outcome of the Study
and the Registry Patients
Randomized
(n  87) p Value
Excluded
Registry
(n  77)
Age, yrs, median (25–75 p) 80 (78–84) 0.02 78 (77–82)
Male gender, n (%) 47 (54) 0.78 39 (51)
Systemic hypertension, n (%) 22 (25) 0.23 15 (19)
Diabetes mellitus, n (%) 18 (21) 0.24 10 (13)
Previous AMI, n (%) 13 (15) 0.008 26 (34)
Anterior AMI, n (%) 42 (48) 0.89 35 (51)*
Previous CABG, n (%) 7 (8) 0.77 5 (6)
Killip class III or IV, n (%) 10 (11) 0.07 14 (18)
In-hospital mortality 11 (13) 0.23 16 (21)
In-hospital reinfarction 7 (8) 0.14 13 (17)
Stroke 4 (5) 1.0 3 (4)
*In eight patients the localization of the infarct was not possible.
AMI  acute myocardial infarction; CABG  coronary artery bypass grafting
surgery.
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plasma, was lower in the angioplasty treated patients,
although this did not reach the level of significance. There
was no difference in mean ejection fraction measured with
radionuclide techniques between the two groups. This
apparent lack of benefit with regard to direct myocardial
salvage may be a similar finding as was observed when
comparing thrombolytic therapy with placebo treatment
(22).
In our experience with angioplasty, we did not encounter
specific age-related problems with performing angioplasty
in old patients as was reflected in the short time from
hospital admission to first balloon inflation. All noncerebral
bleedings in the angioplasty group were related to the
arterial puncture site, and this occurs more frequently in the
elderly (13). The main reason for excluding patients from
our study was the high incidence of nonconclusive ECGs,
and the number of patients with previous AMI in this group
was significantly higher.
Other studies. Recently, the benefits of thrombolytic ther-
apy in the elderly were questioned based on data from the
Medicare Cooperative Cardiovascular Project registry (8).
This observational survey concerned 7,864 patients age 76
to 86 years from a retrospective cohort study but does not
represent randomized data. Although older patients from
the same registry, who received thrombolytic therapy or
primary angioplasty, had a lower mortality at one year
compared with those who did not receive a reperfusion
strategy, only those treated with primary angioplasty had
better survival at 30 days (23,24).
The number of elderly patients with symptomatic coro-
nary artery disease and the relative number of older patients
being treated in Western society is steadily increasing
(25–27). Approximately 30% of all patients presenting with
AMI are 75 years old (27). However, in most studies of
reperfusion therapy in AMI, elderly people are excluded or
represent a very small minority of the study population. In
a pooled analysis of three randomized studies of primary
angioplasty versus thrombolysis in elderly patients (70
years), angioplasty was more effective (14). Furthermore, the
high incidence of comorbidity and contraindications for
thrombolytic therapy makes primary angioplasty an attrac-
tive reperfusion modality in this patient group. On the other
hand, data from a recently published pooled analysis of the
PAMI study group indicate that elderly patients still remain
at an increased risk of death, bleeding, stroke and other
complications despite treatment with primary angioplasty
(28).
Some limitations of our study should be noted. In
contrast with multicenter trials that have included large
numbers of patients undergoing reperfusion therapy for
AMI, our study included only 87 patients from a single
institution. A trial comparing angioplasty with pharmaco-
logic reperfusion therapy cannot be blinded. Furthermore,
the high success rates associated with primary angioplasty
and subsequent clinical outcome are directly related to
technical skills and experience of operators in high volume
interventional centers (29–31).
Conclusions. In this series of patients with AMI who were
older than 75 years, primary coronary angioplasty had a
significant clinical benefit when compared with IV strep-
tokinase therapy.
Our data stress the need for a large community-based
multicenter trial to confirm our conclusion that primary
coronary angioplasty may be the reperfusion therapy of
choice in elderly patients.
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